www.lilly.co.uk

Eli Lilly and Company Limited
Lilly House
Priestley Road
Basingstoke
Hampshire
RG24 9NL
England

Phone +44 (0) 1256 315000

Direct Healthcare Professional Communication

28 January 2019

LARTRUVO® ▼(olaratumab): outcome of required post-approval study did not confirm the clinical benefit of olaratumab in the approved indication

Dear Healthcare Professional,

Eli Lilly and Company in agreement with the European Medicines Agency (EMA) and the Health Products Regulatory Authority (HPRA) would like to inform you of the following:

Summary

- The global phase 3 study (ANNOUNCE) of olaratumab in combination with doxorubicin in patients with advanced or metastatic soft tissue sarcoma (STS) did not confirm the clinical benefit of olaratumab in combination with doxorubicin as compared with doxorubicin, a standard of care treatment.
- As a consequence, no new patients should be prescribed olaratumab.
- While further assessment of the study results is ongoing, physicians may consider continuing olaratumab treatment in patients who experience clinical benefit.
- No new safety concerns were identified during the study and the safety profile was comparable between treatment arms.

Background information

Olaratumab had previously demonstrated an overall survival benefit in soft tissue sarcoma in a US-only randomized phase 2 trial, which led to the accelerated approval by the FDA and conditional marketing authorisation by the European Medicines Agency. Continued approval is contingent upon verification of clinical benefit in the confirmatory trial ANNOUNCE.

The ANNOUNCE study did not confirm the clinical benefit of olaratumab in combination with doxorubicin as compared to doxorubicin, a standard of care treatment. Specifically, the study did not meet the primary endpoints to prolong survival in the overall population (HR: 1.05; Median 20.4 vs. 19.7 months for olaratumab + doxorubicin and doxorubicin, respectively) or in the leiomyosarcoma (LMS) sub-population (HR: 0.95; Median 21.6 vs. 21.9 months for olaratumab + doxorubicin and doxorubicin, respectively). There was no clinical benefit in key secondary efficacy endpoints (progression-free survival in the overall population: HR 1.231 p-value 0.042; median 5.42 months vs. 6.77 months for olaratumab + doxorubicin and doxorubicin, respectively). No new safety concerns were identified and the safety profile was comparable between treatment arms.

As this study did not confirm clinical benefit, Lilly is in the process of reviewing the full results of the ANNOUNCE study and is working with global regulators to determine the appropriate next steps for olaratumab.

While these discussions are ongoing, patients who are currently receiving olaratumab may, in consultation with their physician, continue their course of therapy if receiving clinical benefit.

However, the results of the ANNOUNCE study do not support new patients with soft tissue sarcoma starting olaratumab.

Call for reporting

Healthcare professionals and patients are encouraged to report any adverse events in accordance with the national spontaneous reporting system to the HPRA:

- Online Reporting via the HPRA Website: www.hpra.ie
- Using downloadable form from the HPRA website. An adverse reaction report form can be downloaded from the HPRA Website. This can be sent by Freepost to the HPRA, Pharmacovigilance, Earlsfort Terrace, IRL - Dublin 2 or by email to medsafety@hpra.ie.
- By telephoning the Pharmacovigilance Section of the HPRA, +353 1 6764971

Company Contact Point

Please do not hesitate to contact Eli Lilly and Company Limited for further clarification of your questions at:

Tel: +353 1 664 0446

Email: Medinfo_UKHUB@lilly.com

Yours sincerely,

Dr. Arash Tahbaz MD

Senior Medical Director

Eli Lilly UK, Ireland and Nordics